Previous 10 | Next 10 |
RESEARCH TRIANGLE PARK, N.C., July 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into a collaboration with Er-Kim Pharmaceuticals to commercialize ORLADEYO ® (berotralstat) in Turkey. “We continue ...
RESEARCH TRIANGLE PARK, N.C., July 17, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced its participation at the 2023 US Hereditary Angioedema Association (HAEA) National Summit, which will include the presentation of three abstracts featuring data o...
2023-07-13 10:18:09 ET BioCryst Pharmaceuticals ( NASDAQ: BCRX ) gained ~6% in the morning hours Thursday after Bank of America upgraded the maker of Orladeyo hereditary angioedema (HAE) therapy, citing a recent selloff in company shares. The analyst Tazeen Ahmad raises his ...
2023-07-13 08:27:10 ET Jiuzi ( NASDAQ: JZXN ) +73% . Snail ( SNAL ) +43% . 60 Degrees Pharmaceuticals ( SXTP ) +35% . Applied DNA Sciences ( APDN ) +8% acquires RNA Polymerase Developer Spindle Biotech, Launches LineaIVT( TM ) Platform to Su...
2023-06-12 06:59:39 ET Intellia Therapeutics ( NASDAQ: NTLA ) added ~5% pre-market Monday after announcing new data from its Phase 1/2 trial for its gene editing candidate NTLA-2002 in hereditary angioedema (HAE), a rare genetic disorder characterized by inflammatory attacks. ...
2023-06-01 05:16:01 ET Summary Baker Brothers' 13F portfolio value increased from $16.65B to $18.38B, with the largest five stakes in Seagen, Incyte, BeiGene, ACADIA Pharma, and Madrigal Pharma. The firm disposed of its stakes in Ascendis Pharma A/S and Horizon Therapeutics, while...
RESEARCH TRIANGLE PARK, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc (Nasdaq: BCRX) today announced that the company will present two abstracts featuring data on oral, once-daily ORLADEYO ® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE...
2023-05-31 03:44:45 ET Summary Today, we circle back on BioCryst Pharmaceuticals for the first time in nearly a year. The company's franchise drug continues to have consistent and impressive revenue growth and the company recently improved its balance sheet. Is BioCryst invest...
RESEARCH TRIANGLE PARK, N.C., May 22, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Public Health Institute (ISP) of Chile has granted marketing authorization for oral, once-daily ORLADEYO ® (berotralstat) for the prophylaxis of ...
2023-05-03 14:55:02 ET BioCryst Pharmaceuticals ( NASDAQ: BCRX ) added ~14% on Wednesday to record the biggest intraday gain since February, even as the maker of Orladeyo hereditary angioedema therapy reported lower-than-expected sales for Q1 2023. The Durham, North Carolina...
News, Short Squeeze, Breakout and More Instantly...
BioCryst Pharmaceuticals Inc. Company Name:
BCRX Stock Symbol:
NASDAQ Market:
BioCryst Pharmaceuticals Inc. Website:
RESEARCH TRIANGLE PARK, N.C., July 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2024 financial results on Monday, August 5, 2024. BioCryst management will host a conference call and webcast ...
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO ® (berotralstat) for t...
2024-06-27 04:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...